On the $SYBX revenue booking allegation and the primary source research presented in support of said allegation ("turns out out to be someone who doesn't remember [the] numbers")
Says paid interviews "may be paraphrased, truncated and/or summarized solely at our discretion, and do not always represent a precise transcript... We have not conducted any diligence or other verification"
i). Ginkgo is IP creation biz (a #synbio $TXN/ $INTC/ $AMD) housed in automated CRO (see $PPD $WUXAY $CRL) "on steroids." That gets paid in cash+ stock/royalties
ii). Biology inherently hard to scale, but part of revenue magic of Ginkgo is code reuseability